IBDEI13I ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,19637,1,4,0)
 ;;=4^454.2
 ;;^UTILITY(U,$J,358.3,19637,1,5,0)
 ;;=5^Varicose Veins w/Ulcer&Inflam
 ;;^UTILITY(U,$J,358.3,19637,2)
 ;;=^269821
 ;;^UTILITY(U,$J,358.3,19638,0)
 ;;=397.1^^131^1276^74
 ;;^UTILITY(U,$J,358.3,19638,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19638,1,4,0)
 ;;=4^397.1
 ;;^UTILITY(U,$J,358.3,19638,1,5,0)
 ;;=5^Rheumatic Disease Pulmonary Valve
 ;;^UTILITY(U,$J,358.3,19638,2)
 ;;=^269587
 ;;^UTILITY(U,$J,358.3,19639,0)
 ;;=397.0^^131^1276^75
 ;;^UTILITY(U,$J,358.3,19639,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19639,1,4,0)
 ;;=4^397.0
 ;;^UTILITY(U,$J,358.3,19639,1,5,0)
 ;;=5^Rheumatic Disease Tricuspid Valve
 ;;^UTILITY(U,$J,358.3,19639,2)
 ;;=^35528
 ;;^UTILITY(U,$J,358.3,19640,0)
 ;;=414.3^^131^1276^17
 ;;^UTILITY(U,$J,358.3,19640,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19640,1,4,0)
 ;;=4^414.3
 ;;^UTILITY(U,$J,358.3,19640,1,5,0)
 ;;=5^CAD d/t Lipid Rich Plaque
 ;;^UTILITY(U,$J,358.3,19640,2)
 ;;=^336601
 ;;^UTILITY(U,$J,358.3,19641,0)
 ;;=414.4^^131^1276^16
 ;;^UTILITY(U,$J,358.3,19641,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19641,1,4,0)
 ;;=4^414.4
 ;;^UTILITY(U,$J,358.3,19641,1,5,0)
 ;;=5^CAD d/t Calc Coronary Lesion
 ;;^UTILITY(U,$J,358.3,19641,2)
 ;;=^340518
 ;;^UTILITY(U,$J,358.3,19642,0)
 ;;=425.11^^131^1276^60
 ;;^UTILITY(U,$J,358.3,19642,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19642,1,4,0)
 ;;=4^425.11
 ;;^UTILITY(U,$J,358.3,19642,1,5,0)
 ;;=5^Hypertrophic Subaortic Stenosis
 ;;^UTILITY(U,$J,358.3,19642,2)
 ;;=^340520
 ;;^UTILITY(U,$J,358.3,19643,0)
 ;;=425.18^^131^1276^59
 ;;^UTILITY(U,$J,358.3,19643,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19643,1,4,0)
 ;;=4^425.18
 ;;^UTILITY(U,$J,358.3,19643,1,5,0)
 ;;=5^Hypertrophic Cardiomyopathy
 ;;^UTILITY(U,$J,358.3,19643,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,19644,0)
 ;;=V12.55^^131^1276^54
 ;;^UTILITY(U,$J,358.3,19644,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19644,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,19644,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,19644,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,19645,0)
 ;;=454.9^^131^1276^84
 ;;^UTILITY(U,$J,358.3,19645,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19645,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,19645,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,19645,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,19646,0)
 ;;=271.3^^131^1277^11
 ;;^UTILITY(U,$J,358.3,19646,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19646,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,19646,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,19646,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,19647,0)
 ;;=611.1^^131^1277^16
 ;;^UTILITY(U,$J,358.3,19647,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19647,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,19647,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,19647,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,19648,0)
 ;;=704.1^^131^1277^17
 ;;^UTILITY(U,$J,358.3,19648,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19648,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,19648,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,19648,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,19649,0)
 ;;=251.2^^131^1277^30
 ;;^UTILITY(U,$J,358.3,19649,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19649,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,19649,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,19649,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,19650,0)
 ;;=253.2^^131^1277^34
 ;;^UTILITY(U,$J,358.3,19650,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,19650,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,19650,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,19650,2)
 ;;=^60686
